知名学者引用


        除了所发表论文的被引用频次、期刊质量能够彰显学者的学术影响力以外,被知名学者引用也是一项学术评价的重要指标。
        当前全球学者库认定的知名学者包括:诺贝尔奖、菲尔兹奖、图灵奖等奖项获得者,多个国家的院士,全球学者库“2023全球学者学术影响力排行版”入榜的前10万学者等。

Chen, Yan 同济大学被知名学者引用:27人次(黄金会员以上可以申请导出本人论文被全部知名学者引用的数据)

1. Drew M,Pardoll 美国 Johns Hopkins University 2021美国医学院院士 Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy

2. Topalian, Suzanne L. 美国 Johns Hopkins University 2017美国医学院院士 Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy

3. Nathan E,Lewis 美国 University of California San Diego Computational cell-cell interaction technologies drive mechanistic and biomarker discovery in the tu..

4. 吴德沛 中国 苏州大学 主任医师 Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a ca..

5. Han,Liang 美国 University of Texas MD Anderson Cancer Center Single-cell dissection of tumor microenvironmental response and resistance to cancer therapy

6. Patrick M,Forde 美国 Johns Hopkins University Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy

7. Barbara,Rothen-Rutishauser 瑞士 University of FRIBOURG Dual CSF1R inhibition and CD40 activation demonstrates anti-tumor activity in a 3D macrophage-HER2

8. Tonini, Giuseppe 意大利 University of Campus Biomed Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers

9. Vincenzi, Bruno 意大利 University of Campus Biomed Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers

10. Fortunato,Ciardiello 意大利 Second University of Naples Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combina..

11. Nathalie,Chaput 法国 UNIVERSITE PARIS SACLAY Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combina..

12. Benjamin,Besse 法国 Institute GUSTAVE ROUSSY Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combina..

13. Filippo,de Braud 意大利 Foundation IRCCS Ist Nazl Tumori Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combina..

14. Marina Chiara,Garassino 意大利 Foundation IRCCS Ist Nazl Tumori Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combina..

15. Valter,Torri 意大利 MARIO NEGRI Institute PHARMACOL Research Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combina..

16. Young Kwang,Chae 美国 Northwestern University risk factors for hyperprogressive disease in lung cancer patients using two different definitions

17. Yoon-Koo,Kang 韩国 University of Ulsan Assessment of hyperprogression versus the natural course of disease development with nivolumab with ..

18. Martin,Reck 德国 Grosshansdorf Hospital Assessment of hyperprogression versus the natural course of disease development with nivolumab with ..

19. Paul,Nghiem 美国 University of Washington Assessment of hyperprogression versus the natural course of disease development with nivolumab with ..

20. Taofeek K,Owonikoko 美国 Emory University Assessment of hyperprogression versus the natural course of disease development with nivolumab with ..

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3